Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes both the acute and chronic leukaemia as well as myeloma and lymphoma (Hodgkin's and non-Hodgkin's (NHL)). Despite the varied clinical presentations: what these malignancies share in common are the propensity to relapse, and disease heterogeneity which leads to difficulties in disease control at the time of relapse.
Dr Michelle Poon aims to review the management of patients with relapsed and refractory malignancies and look at the growing role of precision and personalized medicine in the management of these patients.
With a focus on the Singapore context, the talk aims to highlight the current challenges faced and how these have been addressed to optimise care for patients.